Therapeutic Advances in Drug Safety
Therapeutic Advances in Drug Safety is a journal indexed in SJR in Pharmacology (medical) with an H index of 51. It is an CC BY-NC Journal with a Single blind Peer Review review system The scope of the journal is focused on drug safety, clinical toxicology, pharmacology, pharmacotherapeutics. It has an SJR impact factor of 1,165 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,165.
Metrics
Scimago and CountryOfPapers database fields
SJR Impact
1,165
H-index
51
Docs (year)
49
Docs 3y
96
Total refs
2014
Cites 3y
335
Citable 3y
89
Cites/Doc 2y
3.36
Ref/Doc
41.1
Immediate OA
—
Embargoed OA
NPD
Non OA / Submission
- €
Name good journals. Call out predatory ones.
Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.
Researcher reviews
Best articles by citations
Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: scope of the problem
View moreWho should support the costs of severe adverse drug reactions?
View moreDrug safety advances from ICPE 2010
View moreDrug change: 'a hassle like no other'. An in-depth investigation using the Danish patient safety database and focus group interviews with Danish hospital personnel
View moreDofetilide-induced anorexia in an older adult
View moreContinuation of atypical antipsychotic medications in critically ill patients discharged from the hospital: a single-center retrospective analysis
View moreContemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting
View moreComparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database
View moreCombined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks
View moreCase series of docetaxel-induced dorsal hand-foot syndrome
View moreCardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors
View moreCardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications
View moreCan heparins stimulate bone cancer stem cells and interfere with tumorigenesis?
View moreA practical approach to the pharmacological management of hypertension in older people
View moreBisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy
View moreAssessing and predicting drug-induced anticholinergic risks: an integrated computational approach
View moreApplicability of EU(7)-PIM criteria in cross-national studies in European countries
View moreAntithrombotic medicines following intracerebral haemorrhage: where's the evidence?
View moreAntidepressant use in older inpatients: current situation and application of the revised STOPP criteria
View moreAn update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine
View moreAn exploratory factor analysis of the spontaneous reporting of severe cutaneous adverse reactions
View moreAdverse drug reactions in therapeutic hypothermia after cardiac arrest
View moreAcetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks?
View moreAccessing social media information for pharmacovigilance: what are the ethical implications?
View more